CAL-101 (Idelalisib)

CAL-101 (Idelalisib) is an inhibitor of PI3K delta used in studies of PI3K-Akt-mTOR Signaling and DNA Damage Response and related signaling programs. It is especially relevant in autophagy, cancer, and cell signaling models, where defined compound exposure can be linked to growth-factor signaling, survival control, and nutrient-sensing outputs and checkpoint activation, DNA repair, and genome-stability control.

By inhibiting PI3K delta, CAL-101 (Idelalisib) can be used to examine growth-factor signaling, survival control, and nutrient-sensing outputs and checkpoint activation, DNA repair, and genome-stability control. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In autophagy, cancer, and cell signaling models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving PI3K delta
• Pathway perturbation studies connected to PI3K-Akt-mTOR Signaling and DNA Damage Response and related signaling programs
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, CAL-101 (Idelalisib) is appropriate when a defined chemical perturbant is needed to connect PI3K delta with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in autophagy, cancer, and cell signaling models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.